On December 15, 2022 Nex-I reported that it announced the results of an animal model study of ‘HDAC1 (Histone Deacetylase 1) inhibitor’ for immunotherapy refractory cancer at ESMO (Free ESMO Whitepaper) IO (ESMO Immuno-oncology Congress 2022) (Press release, NEX-I, DEC 15, 2022, View Source;mode=VIEW&num=36&category=&findType=&findWord=&sort1=&sort2=&page=2 [SID1234643437]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
According to the poster, NexI administered ‘HDAC1 inhibitor + PD-1 antibody’ in combination to an animal model refractory to cancer immunotherapy drugs. As a result, it increased the infiltration of cytotoxic T cells (CD8 T cells) in the tumor microenvironment (TME) and enhanced the anticancer effect of previously refractory PD-1 antibodies.
Specifically, NexI administered a combination of ‘PD-1 antibody + HDAC1 inhibitor’ to an animal model refractory to immunotherapy, and as a result, tumor size decreased and apoptosis of cancer cells increased compared to mice administered each drug alone. confirmed.
T cell infiltration and antigen-specific T cell expression significantly increased in the combined administration group compared to the single administration group.
A NexI official said, "This poster is a result of showing that sensitivity to existing immune anticancer drugs that were refractory can be increased by suppressing the refractory factor for immunotherapy drugs that NexI has been researching."
Meanwhile, NexI is currently conducting preclinical research on the lead pipeline ‘NXI-101’ and will begin clinical trials targeting solid cancers such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and malignant melanoma in 2024. We plan to enter phase 1.